Have a personal or library account? Click to login
MRI and 11C acetate PET/CT for prediction of regional lymph node metastasis in newly diagnosed prostate cancer Cover

MRI and 11C acetate PET/CT for prediction of regional lymph node metastasis in newly diagnosed prostate cancer

Open Access
|Jan 2018

References

  1. Cai T, Nesi G, Tinacci G, Giubilei G, Gavazzi A, Mondaini N, et al. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J Surg Res 2011; 167: 267-72. 10.1016/j.jss.2009.05.00419783007
  2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37. 10.1016/j.eururo.2013.09.04624207135
  3. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-6.10.1016/S0022-5347(05)65177-411912387
  4. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996; 167: 1503-7. 10.2214/ajr.167.6.89565858956585
  5. Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006; 186: 743-8. 10/2214/AJR.04.168216498101
  6. Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G, et al. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high-risk” prostate cancer compared to MRI or CT. Scand J Urol Nephrol 2003; 37: 382-6. 10.1080/0036559031000630914594685
  7. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2011; 13: 352-61. 10.1007/s11307-010-0337-620490932
  8. Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/ computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011; 60: 125-30. 10.1016/j.eururo.2011.01.015.21292388
  9. Eiber M, Beer AJ, Holzapfel K, Tauber R, Ganter C, Weirich G, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Inves Radiol 2010; 45: 15-23. 10.1097/RLI.0b013e3181bbdc2f
  10. Vag T, Heck MM, Beer AJ, Souvatzoglou M, Weirich G, Holsapfel K, et al. Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiology 2014; 24: 1821-6. 10.1007/s00330-014-3240-8.
  11. von Below C, Daouacher G, Wassberg C, Grzegorek R, Gestblom C, Sörensen J, et al. Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate-and high-risk prostate cancer. Clin Radiol 2016; 71: 328-34. 10.1016/j.crad.2015.12.001.
  12. Vallini V, Ortori S, Boraschi P, Manassero F, Gabelloni M, Faggioni L, et al. Staging of pelvic lymph nodes in patients with prostate cancer: Usefulness of multiple b value SE-EPI diffusion-weighted imaging on a 3.0 T MR system. Eur J Radiol Open 2016; 3: 16-21. 10.1016/j.ejro.2015.11.004.
  13. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-33. 10.1148/radiol.09090413.20177103
  14. Heck MM, Souvatzoglou M, Retz M, Nawroth R, Kübler H, Maurer T, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/ computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol I 2014; 41: 694-701. 10.1007/s00259-013-2634-1.
  15. Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, Hazell S, et al. Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 2011; 17: 7673-83. 10.1158/1078-0432.CCR-11-2048.22038995
  16. Poulsen MH, Bouchelouche K, Hoilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, et al. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012; 110: 1666-71. 10.1111/j.1464-410X.2012.11150.x.22520686
  17. Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med 2013; 54: 699-706. 10.2967/jnumed.112.111153.23471311
  18. Daouacher G, von Below C, Gestblom C, Ahlström H, Grzegorek R, Wassberg C, et al. Laparoscopic extended pelvic lymph node (LN) dissection as validation of the performance of [C]-acetate positron emission tomography/computer tomography in the detection of LN metastasis in intermediate- and high-risk prostate cancer. BJU Int 2016; 118: 77-83. 10.1111/bju.13202.26074275
  19. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98: 19-22.10.1002/ijc.1012711857379
  20. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6. 10.1038/3509058511518967
  21. Vavere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008; 49: 327-34. 10.2967/jnumed.107.04667218199615
  22. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505. 10.1148/radiology.168.2.33936713393671
  23. Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005; 21: 258-62. 10.1002/jmri.2025115723379
  24. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, and Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-52. 10.1161/01.ATV.0000251615.61858.3317139633
  25. Verma S, and Rajesh A. A clinically relevant approach to imaging prostate cancer: review. AJR Am Journal Roentgenol 2011; 196: S1-10 Quiz S11-14. 10.2214/AJR.09.7196
  26. D’Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000; 284: 1280-3.10.1001/jama.284.10.128010979115
  27. Briganti A, Gallina A, Suardi N, Chun FK, Walz J, Heuer R, et al. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU Int 2008; 101: 556-60. 10.1111/j.1464-410X.2007.07321.x18005204
  28. Polanec SH, Andrzejewski P, Baltzer PAT, Helbich TH, Stiglbauer A, Georg D, et al. Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. PLoS One 2017; 12: e0180790. 10.1371/journal.pone.018079028719629
  29. Park SY, Oh YT, Jung DC, Cho NH, Choi YD, Rha KH. Prediction of micrometastasis (< 1 cm) to pelvic lymph nodes in prostate cancer: Role of preoperative MRI. AJR Am J Rroentgenol 2015; 205: W328-34. 10.2214/AJR.14.14138
  30. Batra V, Gautam G, Jaipuria J, Suryavanshi M, Khera R, Ahlawat R. Predictive factors for lymph node positivity in patients undergoing extended pelvic lymphadenectomy during robot assisted radical prostatectomy. Indian J Urol 2015; 31: 217-22. 10.4103/0970-1591.15691826166965
  31. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. 68Ga-PSMA Positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 2016; 70: 553-7. 10.1016/j.eururo.2015.12.05126810345
  32. van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017; 119: 209-15. 10.1111/bju.1354027207581
  33. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol I 2017; 44: 941-9. 10.1007/s00259-017-3631-6
  34. Kallehauge JF, Tanderup K, Haack S, Nielsen T, Muren LP, Fokdal L, et al. Apparent Diffusion Coefficient (ADC) as a quantitative parameter in diffusion weighted MR imaging in gynecologic cancer: Dependence on b-values used. Acta Oncol 2010; 49: 1017-22. 10.3109/0284186X.2010.50030520831490
  35. Sasaki M, Yamada K, Watanabe Y, Matsui M, Ida M, Fujiwara S, et al. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008; 249: 624-30. 10.1148/radiol.249207168118936317
  36. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25.1918640510.1593/neo.81328
  37. Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9: 850-6. 10.1016/S1470-2045(08)70203-1
  38. Thoeny HC, Froehlich JM, Triantafyllou M, Huesler J, Bains LJ, Vermathen P, et al. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology 2014; 273: 125-35. 10.1148/radiol.1413292124893049
DOI: https://doi.org/10.2478/raon-2018-0001 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 90 - 97
Submitted on: Aug 31, 2017
|
Accepted on: Nov 15, 2017
|
Published on: Jan 24, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2018 Catrin von Below, Cecilia Wassberg, Rafael Grzegorek, Joel Kullberg, Charlotta Gestblom, Jens Sörensen, Mauritz Waldén, Håkan Ahlström, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.